[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100571209":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":28,"centralContacts":33,"locations":42,"responsibleParty":57,"collaborators":11,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":11,"eligibilityCriteria":65,"healthyVolunteers":66,"sex":67,"minAge":68,"maxAge":69,"enrollmentInfo":70,"targetDuration":11,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":11,"overallStatus":45,"whyStopped":11,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":88},{"fullName":5,"class":6},"Nurix Therapeutics, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"NX-5948 tablet and capsule under fasted and fed conditions","EXPERIMENTAL",null,[13],"Drug: NX-5948",{"label":15,"type":10,"description":11,"interventionNames":16},"NX-5948 tablet and capsule combined with esomeprazole under fasted conditions",[13,17],"Drug: Esomeprazole",[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"DRUG","NX-5948","Administered orally in tablet or capsule form",[15,9],{"type":20,"name":25,"description":26,"armGroupLabels":27,"otherNames":11},"Esomeprazole","Administered orally in capsule form",[15],[29],{"name":30,"affiliation":31,"role":32},"Study Director","Nurix Therapeutics","STUDY_DIRECTOR",[34,39],{"name":35,"role":36,"phone":37,"phoneExt":11,"email":38},"Angie Badgett, MBA","CONTACT","402-437-6351","angie.badgett@celerion.com",{"name":40,"role":36,"phone":37,"phoneExt":11,"email":41},"Allen Hunt, MD","allen.hunt@celerion.com",[43],{"facility":44,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":11},"Celerion","RECRUITING","Lincoln","Nebraska","68502","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-96.66696,40.8,{"lat":55,"lon":54},{"type":58,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100571209","phase-1-relative-bioavailability-of-nx-5948-tablets-vs-capsules-and-the-effect-of-covariates-on-the-pk-of-nx-5948-tablets-100571209",false,"NCT06717269","Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets","A Phase 1, Open-Label Study in Healthy Volunteers to Evaluate the Relative Bioavailability of NX-5948 Tablets Compared to Capsules, and the Effect of Food and an Acid-reducing Agent on the Pharmacokinetics of NX-5948","Key Inclusion Criteria:\n\n* Healthy, adult, male or female 19-55 years of age\n* Continuous non-smoker who has not used nicotine and tobacco-containing products for at least 3 months prior to the first dosing\n* Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kg\u002Fm2\n* Medically healthy with no clinically significant medical history, physical examination, clinical laboratory profiles, vital signs, or 12-lead safety ECGs at the screening visit, as deemed by the PI or designee\n* Understands the study procedures in the informed consent form (ICF) and be willing and able to comply with the protocol.\n\nKey Exclusion Criteria:\n\n* Mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study\n* Clinically significant history or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neoplastic myeloproliferative, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine or connective tissue diseases or disorders\n* History of any gastrointestinal surgery or cholecystectomy that could impact the PK of NX-5948\n* History or presence of alcohol or drug abuse within the past 2 years\n* History or presence of hypersensitivity, angioedema, or idiosyncratic reaction to the study drug(s) or related compounds\n* History or presence of:\n\n  * Significant multiple and\u002For severe allergies, including anaphylactic reaction.\n  * Personal or family history of prolonged QT syndrome or family history of sudden cardiac death.\n  * Evidence of atrial fibrillation, atrial flutter, complete bundle branch block, Wolff Parkinson-White Syndrome, or cardiac pacemaker.\n  * Adrenal insufficiency.\n  * Skin infection.\n* Female volunteers of childbearing potential\n* Female volunteer with a positive pregnancy test\n* Positive results for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus (HCV) at the screening visit\n* Donation of blood or significant blood loss within 56 days prior to the first dosing\n* Plasma donation within 7 days prior to the first dosing\n* History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.\n* Previous exposure to NX-5948.\n* Participation in another clinical study within 30 days or within 5 half-lives (if known), prior to the first dosing, whichever is longer. The 30-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of Period 1 of the current study.",true,"ALL","19 Years","55 Years",{"count":71,"type":72},18,"ESTIMATED","INTERVENTIONAL",[75],"PHASE1","This is a multiple part, multiple cohort study evaluating the relative bioavailability, food effect, and drug-drug interaction of NX-5948 in healthy volunteers.",[78],"Healthy Volunteer","2026-02-03",{"date":81,"type":82},"2026-02-05","ACTUAL",{"date":84,"type":82},"2024-11-30",{"date":86,"type":72},"2026-08",{"name":5,"class":6},1]